Figure 8 from Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control

LiqCNA estimates of the emergent resistant population correlate with disease burder. A–C, LiqCNA estimation of resistant disease (percentage, red; right y‐axis) and CA125 (kIU/L, blue; left y‐axis) plotted over time for five unique patients. Time 0 = diagnosis. Subclonal ratio of tumor and blood samples is shown by triangles and squares, respectively. Dotted line indicates the start of each new line of chemotherapy, P, platinum‐containing chemotherapy; dashed line, date of patient death. D, Rate of change in the subclonal ratio estimated by LiqCNA in each sequential time point (compared with the diagnostic sample for that patient) plotted against CA125 at the later time point.